Compare HITI & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HITI | CCCC |
|---|---|---|
| Founded | 2009 | 2015 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 213.6M | 185.1M |
| IPO Year | 2021 | 2020 |
| Metric | HITI | CCCC |
|---|---|---|
| Price | $2.43 | $3.54 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $6.13 | ★ $12.20 |
| AVG Volume (30 Days) | 406.7K | ★ 2.8M |
| Earning Date | 06-15-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 16.45 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $35,947,000.00 |
| Revenue This Year | $23.73 | N/A |
| Revenue Next Year | $12.80 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1.02 |
| 52 Week Low | $2.10 | $1.21 |
| 52 Week High | $4.06 | $3.95 |
| Indicator | HITI | CCCC |
|---|---|---|
| Relative Strength Index (RSI) | 49.66 | 65.54 |
| Support Level | $2.36 | $2.37 |
| Resistance Level | $2.69 | $3.82 |
| Average True Range (ATR) | 0.09 | 0.30 |
| MACD | -0.01 | 0.07 |
| Stochastic Oscillator | 34.00 | 70.63 |
High Tide Inc is a downstream-focused retailer of cannabis products, distributor, and seller of smoking accessories and cannabis lifestyle products. It is a vertically integrated company in the Canadian cannabis market with various brands in its portfolio such as Canna Cabana, Fastendr, Queen of Bud, Grasscity, Daily High Club, and others. The company's reportable operating segments are: Bricks and mortar, which generates maximum revenue, and E-commerce. Geographically, it derives maximum revenue from its business in Canada, followed by the United States of America, and other international markets.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.